Two important clinical trials of Ono Pharmaceuticals, Opivo® (generic name: niborumab) demonstrate the benefits of three-year survival in patients   20170911

By Cancer, JPN

Two important clinical trials of Ono Pharmaceuticals, Opivo® (generic name: niborumab) demonstrate the benefits of three-year survival in patients with advanced nonsmall cell lung cancer with a history of treatment  News Release | Ono Pharmaceutical Co., Ltd.

http://www.ono.co.jp/jpnw/PDF/n17_0911_1.pdf
http://www.ono.co.jp/eng/news/pdf/sm_cn170911_1.pdf

More from tokioX :

  1. 💊Ono Enters into Exclusive License Agreement with Karyopharm to Develop and Commercialize Selinexor and KPT-8602, XPO1 Inhibitors  20171012
  2. 💊Bristol-Myers Squibb Company, Opivo® (generic name: niborumab), approved as Fda as a treatment for hepatocellular cancer patients with treatment history with sorafenib  20170927
  3. 👾Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Advanced Non-squamous Non-small Cell Lung Cancer which Has Been Previously Treated with Platinum-based Therapy in Taiwan News Release
  4. Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Unresectable or Metastatic Melanoma in South Korea  20170919
  5. TOCHU Announces Conclusion of Project Contract for Installation of Flue Gas Desulfurization System for Nikola Tesla A coal-fired power plant in Serbia     20170911
  6. ono、Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival and Showed Durable Responses in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
  7. Nidec Develops New Electric Power Steering (EPS) Powerpack for Automobiles  20170911